Can Test Reports Be Reused for UK Medical Device Registration?

Can Test Reports Be Reused for UK Medical Device Registration?

The reuse of test reports for UK medical device registration depends on product classification, testing standards, registration pathway, and laboratory qualification. First, confirm whether the product falls under UKCA or CE UKNI regulatory scope. Then, based on risk classification, choose the self-declaration or notified body review route. For existing reports from NMPA, CE (EU), FDA, or MDSAP, assess whether the testing standards are equivalent to BS/EN standards, whether the laboratory is ISO 17025 accredited, and whether the report is still valid. Key technical documentation includes performance verification, risk management (ISO 14971), clinical evaluation (MEDDEV 2.7/1 rev.4; UK MDR 2002), and localization of labels and instructions. It is recommended to first inventory existing reports, perform gap analysis, arrange supplementary testing for discrepancies, and appoint a UK Responsible Person to maintain certificate control and post-market surveillance. Common risks include incompatible testing standards, unrecognized laboratories, expired reports, or lack of UK representative declaration. For multi-country registration, core data (e.g., biocompatibility, electrical safety, EMC) may be reused but must be converted to UK format with a gap analysis.

Applicable Scenarios and Core Issues

Reusing test reports is a common strategy to reduce redundant testing costs and shorten registration timelines for UK market entry. However, companies often mistakenly believe that all older reports are directly acceptable for UKCA or CE UKNI certification. The core issues are: Are the testing standards aligned with UK requirements? Is the laboratory recognized by UK authorities? Does the report cover the latest regulatory changes? For example, an original EU CE MDD report may require updated clinical evaluation or label changes under UK MDR 2002. Applicable scenarios include products already holding CE, FDA, NMPA, or MDSAP certification; multi-country submissions with unified technical files; or reports that are still valid but need gap assessment. Key decision points include product risk class (I/IIa/IIb/III), special materials or drug coatings, and existence of UK-specific standards (e.g., BS EN 60601).

Registration Decision Logic

Step 1: Confirm the product qualifies as a medical device under UK MDR 2002 and is not within border control exclusions.
Step 2: Determine risk class: Class I allows self-declaration; Class IIa/IIb/III require a notified body.
Step 3: Choose the registration pathway: UKCA (for Great Britain) or CE UKNI (for Northern Ireland).
Step 4: Evaluate existing test reports: Are standards equivalent? Is the laboratory listed under UKAS accreditation or an international mutual recognition arrangement? Is the report within its valid period (typically 3–5 years)? If standards differ, provide a gap analysis (e.g., IEC 60601-1 3rd ed. vs. BS EN 60601-1 3rd ed.) and possibly perform additional tests. If the laboratory is not on the recognized list, retest or provide evidence of equivalent capability (e.g., ISO 17025 certificate under ILAC-MRA). For higher-risk products, a clinical evaluation report (CER) or performance study may be required.

Required Documentation and Evidence

To reuse test reports, prepare: original test report (including test methods, results, device information); laboratory accreditation certificate (ISO 17025, UKAS or ILAC logo); standard comparison document (listing differences and impact on results); overall test summary or performance verification protocol; risk management report (ISO 14971) analyzing test coverage; clinical evaluation plan or report (if applicable); labels and instructions for use (compliant with UK language and symbols). For multi-country registration, include statements on report acceptance by each regulator. For example, in GHWP member states, Southeast Asian countries are more accepting of equivalent standards, while Latin American countries may require local clinical data. MDSAP reports (if applicable) are recommended to strengthen evidence.

Common Mistakes

• Assuming all CE reports are directly valid for UKCA: Ignoring differences between Great Britain and Northern Ireland, or misjudging notified body eligibility (UKCA requires a UK Approved Body, not an EU Notified Body).
• Using expired reports: Failing to check report validity or standard version updates (e.g., new IEC standard transition periods).
• Not verifying laboratory accreditation: Using reports from non-ISO 17025 accredited labs or labs rejected by UK authorities.
• Missing UK Representative declaration: Failing to appoint a UK Responsible Person, rendering registration invalid.
• Neglecting label localization: Not converting CE marks to UKCA marks or adding UKSI numbers.

Preparation Checklist for Companies

• Collect all existing test reports, categorize by test item, standard version, and laboratory name.
• Create a comparison table between BS EN standards and international standards (e.g., IEC, ISO, GB).
• Verify laboratory accreditation: ISO 17025 certificate and UKAS or ILAC-MRA recognition.
• Check report validity: within reasonable lifespan, not outdated, and covering new risks.
• Prepare UK Responsible Person agreement (contract).
• Structure technical file in line with UK MDR 2002 Annex requirements.
• Develop a supplementary testing plan or justification for discrepancies.
• Establish change control process for notifying UK Representative and notified body of report updates.

AIMEILI Perspective

The most common misjudgment is assuming that a CE approval automatically qualifies for UKCA, overlooking differences in standard versions and laboratory qualifications. Early gap analysis and laboratory accreditation verification are crucial. Test report reuse offers high value but requires local adaptation: for example, clinical evaluation based on EU population data may need adjustment, and labels must be translated into English and comply with UK requirements. In multi-country registration, core tests (electrical safety, EMC, biocompatibility) can be reused, but a gap assessment must be provided for each market. Particularly, when appointing a UK Responsible Person, ensure clarity on their responsibilities for certificate control and change notifications to avoid certificate invalidation due to agent changes. It is recommended to create a “Test Report Reuse Matrix” per product, listing report source, standard, validity, applicable markets, and required supplementary work to reduce rework and risk of non-compliance.

Frequently Asked Questions

Q1: Can I directly apply for UKCA marking if I already hold an EU CE certificate?

No, direct conversion is not possible. Under UK MDR 2002, assessment by a UK Approved Body is required. Alternatively, the CE certificate may be used for UKCA during a transitional period (until July 2025) only if specific conditions are met (e.g., certificate issued before 1 January 2021). Test reports must include gap analysis to BS EN standards, and a UK Representative must be appointed.

Q2: Are test reports from Chinese CNAS-accredited laboratories acceptable in the UK?

If the laboratory is ISO 17025 accredited under CNAS and CNAS has a mutual recognition agreement with UKAS (ILAC-MRA), the reports may be accepted in principle. However, UK notified bodies may request original data or additional tests. It is advisable to choose laboratories with international mutual recognition and communicate with the notified body in advance.

Q3: Do test report updates after product launch affect UK registration?

Yes. Any changes affecting safety or performance (e.g., raw material changes, revised test methods) must be notified to the UK Representative and may require supplementary reports or re-assessment. The change control process should be clearly documented and aligned with UK MDR 2002 post-market surveillance requirements.